ORGANIZERS

Dr. Hemant Tongaonkar
Consultant Urologic Oncologist
Hinduja Hospital & Research Center, Mumbai

Dr. Ganesh Bakshi
Professor, Uro-Oncology
Tata Memorial Hospital, Mumbai

Dr. Santosh Menon
Professor, Pathology
Tata Memorial Centre, Mumbai

On behalf of

1st COMPREHENSIVE UPDATE ON
GENITO-URINARY MALIGNANCIES

Wisdom of Waves

- Highlights of AUA & EAU 2018
- Opinion based Consensus
- Case based MDT

SCIENTIFIC PROGRAMME

30th June & 1st July, 2018. Tata Auditorium, Tata Memorial Hospital

Conference Secretariat:
Mr. Saurabh Desai / Mr. Devraj Chhaperwal
Mob: 9773384808 / 9820392657 Tel: 022-24931359
08:00 to 09:00
Registration

08:30 to 09:00
Opening remarks; Welcome Address & Inauguration of UCF
Dr. H. B. Tongaonkar

Prostate cancer
09:00 to 09:45
Screening & Diagnosis of Early Prostate Cancer

Chairpersons: Dr. H. B. Tongaonkar, Dr. Ajit Vaze

Presenters:
- Dr. Abhijit Bapat - EAU 61, 266
- Dr. Mahendra Pal - EAU 269, 629

Moderator: Dr. Bhalchandra Kashyapi

Panelists:
- Dr. Nitin Kekre
- Dr. Hemant Pathak
- Dr. Palak Popat
- Dr. N. Ragavan
- Dr. Vedang Murthy
- Dr. S. K. Raghunath

Abstracts

1. EAU 61: LONG TERM OUTCOMES FOR MEN IN A SCREENING TRIAL WITH AN INITIAL BENIGN BIOPSY: A POPULATION-BASED COHORT

2. EAU 266: SCREENING & PROSTATE CANCER MORTALITY: RESULTS OF A UNIQUE COHORT AT 19 YEARS OF FOLLOW-UP

3. EAU 269: UNINTENDED CONSEQUENCES OF DECREASED PSA-BASED PROSTATE CANCER SCREENING

4. EAU 629: WHICH PATIENTS SHOULD CONSIDER & WHICH PATIENTS COULD SAFELY AVOID PROSTATE BIOPSY IN THE SETTING OF NEGATIVE MPMRI?
Day 1, Saturday, 30th June 2018

09:45 to 10:30

Active Surveillance

Chairpersons: Dr. Percy Chibber, Dr. Lalmalani

Presenters: Dr. Asawari Ambekar - EAU 164, 09:45 to 09:50
Dr. Ginil Kumar - EAU 64, AUA MP 12-06, 12-07 09:50 to 10:05

Moderator: Dr. Gagan Prakash 10:05 to 10:30

Panelists: Dr. Kalyan Sarkar, Dr. Karthik Ganesan, Dr. Vedang Murthy,
Dr. Hemang Bakshi, Dr. Bijal Kulkarni, Dr. Abhijit Bapat.

Abstracts

1. EAU 164: GLEASON SCORE 6 PROSTATE CANCER IS NOT ALWAYS HARMLESS
2. EAU 64: CAN ACTIVE SURVEILLANCE REALLY REDUCE THE HARMS OF OVERDIAGNOSING PROSTATE CANCER?
3. AUA MP 12-06: LONG-TERM RISK OF METASTATIC PROSTATE CANCER IN MEN WITH GRADE GROUP 2 MANAGED WITH ACTIVE SURVEILLANCE
4. AUA MP 12-07: TARGETED BIOPSIES IN MEN ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER: WHEN IS UPGRADE INCREASED RISK?

10:30 to 10:45

TEA BREAK

10:45 to 12:45

Localized & locally Advanced Prostate Cancer

Chairpersons: Dr. S. K. Srivastava, Dr. M. R. Kamat

Presenters: Dr. Ritesh Purthy - AUA PD 10-02, EAU 394 10:45 to 10:55
Dr. Gagan Prakash - EAU 405, EAU 356, AUA -PD37-01 10:55 to 11:10
Dr. Ashish Singh - EAU 604, EAU 400 11:10 to 11:20
Dr. Pranav Chadha - EAU PT 79, EAU PT 86, EAU 397, AUA MP 22-05 11:20 to 11:45

Abstracts

1. EAU 405: PROSPECTIVE EVALUATION OF THE PERFORMANCE OF 68GA-PSMA 11-PET CT/MRI IMAGING FOR LYMPH NODE STAGING IN PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY
2. EAU 400: ASSESSING THE NEED FOR & THE OPTIMAL DURATION OF HORMONAL THERAPY IN ASSOCIATION WITH POST-PROSTATECTOMY RADIATION THERAPY: RESULTS FROM A MULTI-INSTITUTIONAL STUDY
3. EAU 356: CHITOSAN MEMBRANES APPLIED ON THE NEUROVASCULAR BUNDLES DURING NERVE SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY: UPDATED RESULTS OF A PHASE II STUDY
4. EAU 604: PROSTATE-SPECIFIC ANTIGEN (PSA) RESPONSE IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MD CRPC) TREATED WITH ENZALUTAMIDE (ENZA)
5. EAU PT 079: WHICH PATIENTS SHOULD BE STILL CONSIDERED FOR LATE SALVAGE RADIOTHERAPY FOR RISING OR PERSISTENTLY ELEVATED PSA AFTER RADICAL PROSTATECTOMY: RESULTS FROM A LARGE MULTI-INSTITUTIONAL STUDY
6. EAU PT 086: THE PROGNOSTIC ROLE OF EARLY PSA RESPONSE AFTER SALVAGE RADIATION THERAPY
7. EAU 394: IS IT WORTH TO PERFORM RADICAL PROSTATECTOMY IN A SALVAGE SETTING? RESULTS OF A CONTEMPORARY MULTICENTRE SERIES OF 395 CASES
8. EAU 397: WHAT IS THE OPTIMAL FIELD OF POST-PROSTATECTOMY RADIATION THERAPY? LONG-TERM RESULTS FROM A MULTI-INSTITUTIONAL STUDY
9. AUA MP 22-05: TESTING THE IMPACT OF ADJUVANT RADIOTHERAPY (ART) AFTER RADICAL PROSTATECTOMY (RP) ON OVERALL MORTALITY (OM) IN PROSTATE CANCER PATIENTS WITH PATHOLOGICALLY NODE POSITIVE DISEASE
10. AUA PD 10-02: ADJUVANT RADIATION WITH BROWN DEPRIVATION THERAPY FOR MEN WITH LYMPH NODE METASTASES FOLLOWING RADICAL PROSTATECTOMY
11. AUA PD 37-01: THE CLINICAL EFFICACY OF PSMA PET/MRI IN BIOCHEMICALLY RECURRENT PROSTATE CANCER COMPARED WITH STEROID CARE IMAGING MODALITIES - RESULTS OF A MULTICENTRE, PROSPECTIVE CLINICAL TRIAL
Day 1, Saturday, 30th June 2018

**Metastatic Prostate Cancer**

**Chairpersons:** Dr. Suresh Babu, Dr. H. B. Tongaonkar

**Presenters:**
- Dr. Ashish Joshi - EAU 609, EAU 111 13:30 to 13:40
- Dr. Vashishta Maniar - AUA MP 52-10, EAU PT 087 13:40 to 13:50
- Dr. Prasanth Penumadu - EAU 408, AUA MP 52-09 13:50 to 14:00

**Moderator:** Dr. Amit Joshi 14:00 to 14:45

**Panelists:** Dr. Sachin Almel, Dr. Janak Desai, Dr. Nagraj H, Dr. Mangesh Patil, Dr. Sandeep De, Dr. N. Ragavan, Dr. Mukund Andankar, Dr. Vanita Noronha

**Abstracts**

1. **EAU 609:** AR-V7 in Peripheral Whole Blood of Castration-Resistant Prostate Cancer Patients: Association with Treatment-Specific Outcome under Abiraterone & Enzalutamide

2. **EAU 408:** Local Treatment of Metastasis Improves Oncological Outcome in Men with Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy (CRP) for Metastatic Prostate Cancer (MPCA);

3. **EAU PT 087:** Survival Benefit of Local vs. No Local Treatment for Metastatic Prostate Cancer - Impact of Baseline PSA & Metastatic Substages

4. **EAU 111:** Transcribed Ultraconserved Region UC.63+ Promotes Resistance to Docetaxel Through AR Signaling & a Promising Serum Biomarker for Docetaxel Treatment in Prostate Cancer

5. **AUA MP 52-09:** Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LOMP) Trial: Interim Analysis of Clinical Outcomes & Prognostic Factors;

6. **AUA MP 52-10:** Optimal Sequencing Strategy Using Docetaxel & Androgen Receptor Axis-Targeted Agents in Patients with Castration-Resistant Prostate Cancer: Utilization of Neutrophil-to-Lymphocyte Ratio

---

**Renal cancer**

**Early Renal Cancer & SRM**

**Chairpersons:** Dr. Venkatesh Krishnamurthy, Dr. Rajeev Sood

**Presenters:**
- Dr. Ritesh Purthy - AUA MP48-15 14:45 to 14:55
- Dr. Randeep Singh - AUA PD57-09 14:55 to 15:05

**Moderator:** Dr. Ginil Kumar 15:05 to 15:25

**Panelists:** Dr. Gaurang Shah, Dr. Ranjan Dey, Dr. Gagan Prakash, Dr. Kathiresan, Dr. Bhupender Singh, Dr. Divya Midha

**Abstracts**

1. **AUA MP 48-15:** Does Partial Nephrectomy for Biopsy Proven Fuhrman Grade 3/4 Renal Cell Carcinoma Confer Worse Outcomes Compared to Radical Nephrectomy?

2. **AUA PD 57-09:** Systematic Review & Meta-Analysis of Adjuvant Therapy after Nephrectomy for High-Risk, Non-Metastatic Renal Cell Carcinoma

**TEA BREAK**
Day 1, Saturday, 30th June 2018

15:45 to 16:45
Advanced & Metastatic Renal Cancer
Chairpersons: Dr. Asha Kapadia, Dr. Kalyan Sarkar
Presenters:
- Dr. Prasanth Penumadu - EAU 304, AUA MP 59-04 15.45 to 15.55
- Dr. Gagan Gautam - AUA PD 24-03, CARMENA 15.55 to 16.10
Moderator: Dr. Senthil Rajappa 16.10 to 16.45
Panelists: Dr. B. K. Smruti, Dr. Nilesh Sable, Dr. Avinash Deo, Dr. H. B. Tongaonkar, Dr. Mahendra Pal, Dr. Amit Joshi

Abstracts
1. EAU 304: CONTRAST MEDIA ENHANCEMENT REDUCTION PREDICTS TUMOR RESPONSE TO PRESURGICAL MOLECULAR-TARGETING THERAPY IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
2. AUA MP 59-04: IS THERE A ROLE FOR NEPHRON SPARING CYTOREDUCTIVE PARTIAL NEPHRECTOMY IN METASTATIC RENAL CELL CARCINOMA?
3. AUA PD 24-03: SURVIVAL FOLLOWING UFRONT CYTOREDUCTIVE NEPHRECTOMY VERSUS TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA
4. CARMENA: CYTOREDUCTIVE NEPHRECTOMY FOLLOWED BY SUNITINIB VERSUS SUNITINIB ALONE IN METASTATIC RENAL CELL CARCINOMA RESULTS OF A PHASE III NONINFERIORITY TRIAL

Dispersal
18:30 to 20:30
Workshop on updates in the management of Metastatic Prostate Cancer
Supported by educational grant from Astellas
20:30 to 22:00
DINNER, ITC

Day 2, Sunday 01st July 2018

09:30 to 10:00
BREAKFAST

Bladder Cancer

10:00 to 10:45
NMIBC
Chairpersons: Dr. S. K. Rawal, Dr. Murali Kamat, Dr. N. P. Gupta
Presenters:
- Dr. Abhay - EAU 735, AUA MP 08-20 10.00 to 10.10
- Dr. Rakesh Sharma - EAU 733, EAU 732 10.10 to 10.20
Moderator: Dr. Rakesh Sharma 10.20 to 10.45
Panelists: Dr. Shrikant Badwe, Dr. Venkatesh Krishnamurthy, Dr. Satyakam, Dr. H. B. Tongaonkar, Dr. Janak Desai

Abstracts
1. EAU 735: CONTINUOUS SALINE BLADDER IRRIGATION AFTER TRANSURETHRAL RESECTION IS AN ALTERNATIVE PROPHYLACTIC STRATEGY FOR THE PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER
2. AUA MP 08-20: OVERNIGHT CONTINUOUS SALINE IRRIGATION AFTER TRANSURETHRAL RESECTION FOR SUPERFICIAL BLADDER CANCER IS HELPFUL IN PREVENTION OF EARLY RECURRENCE
3. EAU 733: EARLY VERSUS DELAYED RADICAL CYSTECTOMY FOR CLINICAL T1 BLADDER CANCER;
4. EAU 732: ONCOFOID-P-B (PACLITAXEL-HYALURONIC ACID) IN THE INTRAVESICAL THERAPY OF PATIENTS AFFECTED BY PRIMARY OR RECURRENT TA G1-G2 PAPILLARY CANCER OF THE BLADDER. A PHASE II MARKER LESION STUDY
Day 2, Sunday 01st July 2018

10:45 to 11:30

MIBC

Chairpersons: Dr. Nitin Kekre

Presenters: Dr. Prasanth Penumadu - EAU 365, EAU 367
Dr. Nirmal Raut - EAU 715, AUA PD 11-11

Moderator: Dr. Sanjay Addla

Panelists: Dr. Sudhir Rawal, Dr. Amlesh Seth, Dr. Chirag Desai, Dr. Bhupender Singh,
Dr. S. Patwardhan, Dr. Percy Chibber, Dr. Giniil Kumar,
Dr. Boman Dhabhar, Dr. Amit Joshi

Abstracts

1. EAU 365: RADICAL CYSTECTOMY PROVIDES IMPROVED SURVIVAL OUTCOMES & DECREASED COSTS COMPARED WITH TRIMODAL THERAPY FOR PATIENTS DIAGNOSED WITH LOCALIZED MUSCLE-INVASIVE BLADDER CANCER
2. EAU 715: NEOADJUVANT CHEMOTHERAPY DOES NOT INCREASE MORBIDITY OF RADICAL CYSTECTOMY - A 10-YEAR NATIONWIDE STUDY
3. EAU 367: RRC-PENTAFECTA: A PROPOSAL FOR STANDARDIZATION OF OUTCOMES REPORTING FOLLOWING ROBOT ASSISTED RADICAL CYSTECTOMY
4. AUA PD 11-11: INTERIM RESULTS FROM PURE-01: A PHASE 2, OPEN-LABEL STUDY OF NEOADJUVANT PEMBROLIZUMAB (PEMBO) BEFORE RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA (MIUC) &REA NECCHI*

11:30 to 11:45

TEA

11:45 to 13:00

Advanced & Metastatic Bladder Cancer

Chairpersons: Dr. S. H. Advani, Dr. Asha Kapadia

Presenters: Dr. Sewanti Limaye - EAU 460, EAU 91
Dr. Nirmal Raut - EAU 86, EAU 87
Dr. Randeep Singh - AUA MP 78-07, AUA MP PD 15-11

Moderator: Dr. Mehboob Basade

Panelists: Dr. Avinash Deo, Dr. Priya Tiwari, Dr. Joydeep Ghosh,
Dr. Abhijit Bapat, Dr. Gagan Prakash

Abstracts

1. EAU 460: BIOLOGICAL CHARACTERIZATION OF CISPLATIN-RESISTANT BLADDER CANCER: IMPLICATIONS FOR SECOND-LINE TREATMENTS?
2. EAU 91: SUPERIOR EFFICACY OF NEOADJUVANT CHEMOTHERAPY & RADICAL CYSTECTOMY IN CT3-4 ANOMO COMPARED TO CT2N0M0 BLADDER CANCER
3. EAU 87: ADJUVANT IMMUNOTHERAPY AFTER CYSTECTOMY FOR MIBC PATIENTS: LESSONS LEARNED FROM THE PHASE II CLINICAL TRIAL ‘MAGNOLIA’
4. EAU 86: PEMBROLIZUMAB (PEMBO) AS FIRST-LINE THERAPY IN ELDERLY PATIENTS (PTS) WITH POOR PERFORMANCE STATUS WITH CISPLATIN-INELIGIBLE ADVANCED UROTHELIAL CANCER (UC): RESULTS FROM KEYNOTE-052;
5. AUA MP 78-07: CLINICAL CHARACTERISTICS ASSOCIATED WITH EARLY PROGRESSION OR LONG-TERM RESPONSE FROM THE PHASE II IMVIGOR210 STUDY: ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
6. AUA PD 15-11: THE VALUE OF NEOADJUVANT CHEMOTHERAPY IN CLINICALLY NODE-POSITIVE BLADDER CANCER Ryan Werntz*

END of Conference
Closing Remarks by Dr. Hemant Tongaonkar.

13:00 to 14:00

LUNCH